Endocrine Abstracts

Differentiated thyroid cancer (DTC) is the most common malignant neoplasm arising from the thyroid parenchymal cells. DTC incidence is steadily increasing worldwide and there are approximately 1700 new cases/per year in Poland. The biopsy with subsequent thyroid resection plays a central role in the diagnosis and treatment of this malignancy. After surgery, radioactive iodine (RAI) treatment is recommended to eradicate potential residual disease and improve prognosis. Due to t...

Differentiated thyroid cancer (DTC) is the most common malignant neoplasm arising from the thyroid parenchymal cells. DTC risk stratification is a multi-stage process based on investigated histopathological features and ultrasound test outcomes combined with biochemical test results. Thus, searching for novel diagnostic indicators useful in cancer risk stratification are still needed. Recent studies revealed that oxidative and epigenetic alterations in DTC represent the signat...

Hashimoto disease, a chronic autoimmune lymphocytic thyroiditis, is the most common cause of hypothyroidism with a prevalence of 10–12% in the general population. Literature data suggests that persistently high levels of oxidative are considered as relevant risk factor in the occurrence and development of autoimmune diseases, including Hashimoto. The DNA and RNA are particularly valuable to the oxidative damage, and guanine is the most prone base to oxidation. Thus, the D...

The most effective conventional treatment for differentiated thyroid cancer (DTC) still remains total thyroidectomy with subsequent adjuvant therapy with radioiodine ablation (RAI). In case of unsuccessful RAI treatment, an alternative method is the tyrosine kinase inhibitor therapy. However, its usage is related to many side effects and is not well tolerated by patients. Despite the great progress in the clinical management of patients with DTC, the lack of alternative therap...